Symbols / ATHE
ATHE Chart
About
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 60.29M |
| Enterprise Value | 30.59B | Income | -12.15M | Sales | 5.44M |
| Book/sh | 0.00 | Cash/sh | 0.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 9 | IPO | — |
| P/E | — | Forward P/E | -8.41 | PEG | — |
| P/S | 11.08 | P/B | 942.22 | P/C | — |
| EV/EBITDA | -2090.36 | EV/Sales | 5624.05 | Quick Ratio | 12.62 |
| Current Ratio | 12.98 | Debt/Eq | 0.37 | LT Debt/Eq | — |
| EPS (ttm) | -0.59 | EPS next Y | -0.40 | EPS Growth | — |
| Revenue Growth | 80.90% | Earnings | 2015-08-25 20:00 | ROA | -28.09% |
| ROE | -43.23% | ROIC | — | Gross Margin | 97.66% |
| Oper. Margin | -185.73% | Profit Margin | -223.35% | Shs Outstand | 18.13M |
| Shs Float | 7.04B | Short Float | 0.01% | Short Ratio | 0.10 |
| Short Interest | — | 52W High | 7.00 | 52W Low | 2.52 |
| Beta | -0.02 | Avg Volume | 14.14K | Volume | 1.42K |
| Target Price | $11.00 | Recom | Strong_buy | Prev Close | $3.30 |
| Price | $3.33 | Change | 0.79% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.00
Mean price target
2. Current target
$3.33
Latest analyst target
3. DCF / Fair value
$-8.60
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.33
Low
$10.00
High
$12.00
Mean
$11.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-17 | init | Canaccord Genuity | — → Speculative Buy | — |
| 2025-01-30 | main | Maxim Group | Buy → Buy | $12 |
| 2024-12-12 | init | Maxim Group | — → Buy | $8 |
| 2024-03-07 | reit | Benchmark | Speculative Buy → Speculative Buy | $4 |
| 2023-06-05 | main | Ladenburg Thalmann | Buy → Buy | $10 |
- Experimental MSA drug ATH434 inches toward Phase 3 on stronger data - Stock Titan Fri, 30 Jan 2026 08
- European shares advance on Nvidia results lift; investors assess US jobs data - Reuters hu, 20 Nov 2025 08
- Meet the team who treats injured cowboys at the stock show - 9News hu, 22 Jan 2026 08
- Sports Bets at the Stock Exchange - Bloomberg.com ue, 07 Oct 2025 07
- Where to Eat During the National Western Stock Show - 5280 hu, 08 Jan 2026 08
- Aiming for first MSA therapy, Alterity targets $2.4B opportunity - Stock Titan Wed, 21 Jan 2026 08
- Morning Bid: Great stock rotation rolls on - Reuters Wed, 14 Jan 2026 08
- Strategy Announces $21 Billion STRK At-The-Market Program - Strategy Mon, 10 Mar 2025 07
- Trump says he's not even looking at stock market, tariffs will make U.S. 'very strong' - CNBC hu, 06 Mar 2025 08
- Alterity (NASDAQ: ATHE) schedules Nov. 19 presentation at Bell Potter virtual conference - Stock Titan Wed, 12 Nov 2025 08
- Showing cattle at the National Western Stock Show is a whirlwind of work and tradition for Yuma's Weathers family - Colorado Public Radio Mon, 27 Jan 2025 08
- European shares flat ahead of Fed decision; investors assess mixed corporate updates - Reuters Wed, 10 Dec 2025 08
- European shares subdued at close amid caution ahead of week's Fed rate decision - Reuters Mon, 08 Dec 2025 08
- Breakthrough MSA Drug Trial Reaches Major Milestone: What's Next for This Rare Disease Treatment? - Stock Titan hu, 27 Mar 2025 07
- European shares end flat as Trump tones down Greenland rhetoric - Reuters Wed, 21 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -20.13K | 78.35K | 280.44K | 816.73K |
| TaxRateForCalcs | 0.30 | 0.30 | 0.30 | 0.30 |
| NormalizedEBITDA | -12.13M | -19.52M | -15.20M | -17.81M |
| TotalUnusualItems | -67.11K | 261.15K | 934.80K | 2.72M |
| TotalUnusualItemsExcludingGoodwill | -67.11K | 261.15K | 934.80K | 2.72M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -12.15M | -19.12M | -13.81M | -12.85M |
| ReconciledDepreciation | 139.72K | 147.53K | 102.26K | 54.21K |
| EBITDA | -12.19M | -19.25M | -14.27M | -15.08M |
| EBIT | -12.33M | -19.40M | -14.37M | -15.14M |
| NetInterestIncome | 446.29K | 268.42K | 16.44K | 2.50K |
| InterestIncome | 446.29K | 268.42K | 16.44K | 2.50K |
| NormalizedIncome | -12.10M | -19.31M | -14.46M | -14.75M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -12.15M | -19.12M | -13.81M | -12.85M |
| TotalExpenses | 12.33M | 19.40M | 14.37M | 15.14M |
| RentExpenseSupplemental | 68.63K | 79.33K | 87.61K | |
| DilutedAverageShares | 10.66M | 6.08M | 24.28M | 4.01M |
| BasicAverageShares | 10.66M | 6.08M | 24.28M | 4.01M |
| DilutedEPS | -1.14 | -3.12 | -0.57 | -3.18 |
| BasicEPS | -1.14 | -3.12 | -0.57 | -3.18 |
| DilutedNIAvailtoComStockholders | -12.15M | -19.12M | -13.81M | -12.85M |
| NetIncomeCommonStockholders | -12.15M | -19.12M | -13.81M | -12.85M |
| NetIncome | -12.15M | -19.12M | -13.81M | -12.85M |
| NetIncomeIncludingNoncontrollingInterests | -12.15M | -19.12M | -13.81M | -12.85M |
| NetIncomeContinuousOperations | -12.15M | -19.12M | -13.81M | -12.85M |
| TaxProvision | 68.06K | 46.09K | 104.46K | 70.01K |
| PretaxIncome | -12.08M | -19.08M | -13.70M | -12.78M |
| OtherIncomeExpense | -192.38K | 56.52K | 649.73K | 2.36M |
| OtherNonOperatingIncomeExpenses | -125.27K | -204.63K | -285.07K | -364.67K |
| GainOnSaleOfSecurity | -67.11K | 261.15K | 934.80K | 2.72M |
| NetNonOperatingInterestIncomeExpense | 446.29K | 268.42K | 16.44K | 2.50K |
| InterestIncomeNonOperating | 446.29K | 268.42K | 16.44K | 2.50K |
| OperatingIncome | -12.33M | -19.40M | -14.37M | -15.14M |
| OperatingExpense | 12.33M | 19.40M | 14.37M | 15.14M |
| OtherOperatingExpenses | -2.12M | 5.24K | 27.30K | -452.96K |
| OtherTaxes | -5.44M | -4.02M | -3.91M | -4.67M |
| DepreciationAmortizationDepletionIncomeStatement | 139.72K | 147.53K | 102.26K | 54.21K |
| DepreciationAndAmortizationInIncomeStatement | 139.72K | 147.53K | 102.26K | 54.21K |
| DepreciationIncomeStatement | 139.72K | 147.53K | 102.26K | 54.21K |
| ResearchAndDevelopment | 14.40M | 18.64M | 13.20M | 14.75M |
| SellingGeneralAndAdministration | 5.34M | 4.62M | 4.95M | 5.46M |
| GeneralAndAdministrativeExpense | 5.34M | 4.62M | 4.95M | 5.46M |
| OtherGandA | 2.77M | 2.55M | 2.27M | 2.51M |
| InsuranceAndClaims | 549.41K | 676.22K | 721.73K | 655.99K |
| RentAndLandingFees | 68.63K | 79.33K | 87.61K | |
| SalariesAndWages | 2.03M | 1.40M | 1.89M | 2.21M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| OrdinarySharesNumber | 9.13B | 5.25B | 2.44B | 2.41B |
| ShareIssued | 9.13B | 5.25B | 2.44B | 2.41B |
| TotalDebt | 155.46K | 159.04K | 210.38K | 117.49K |
| TangibleBookValue | 42.40M | 13.80M | 22.81M | 35.47M |
| InvestedCapital | 42.40M | 13.80M | 22.81M | 35.47M |
| WorkingCapital | 42.34M | 13.66M | 22.67M | 35.32M |
| NetTangibleAssets | 42.40M | 13.80M | 22.81M | 35.47M |
| CapitalLeaseObligations | 155.46K | 159.04K | 210.38K | 117.49K |
| CommonStockEquity | 42.40M | 13.80M | 22.81M | 35.47M |
| TotalCapitalization | 42.40M | 13.80M | 22.81M | 35.47M |
| TotalEquityGrossMinorityInterest | 42.40M | 13.80M | 22.81M | 35.47M |
| StockholdersEquity | 42.40M | 13.80M | 22.81M | 35.47M |
| OtherEquityInterest | 5.34M | 4.81M | 3.97M | 3.57M |
| GainsLossesNotAffectingRetainedEarnings | 3.57M | 2.75M | ||
| RetainedEarnings | -225.89M | -214.16M | -195.13M | -181.88M |
| CapitalStock | 262.95M | 223.15M | 213.97M | 213.79M |
| CommonStock | 262.95M | 223.15M | 213.97M | 213.79M |
| TotalLiabilitiesNetMinorityInterest | 3.62M | 5.43M | 4.50M | 5.89M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 88.55K | 51.91K | 122.71K | 73.61K |
| EmployeeBenefits | 0.00 | 19.50K | 13.75K | 9.77K |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 0.00 | 19.50K | ||
| LongTermDebtAndCapitalLeaseObligation | 88.55K | 51.91K | 103.21K | 59.86K |
| LongTermCapitalLeaseObligation | 88.55K | 51.91K | 103.21K | 59.86K |
| CurrentLiabilities | 3.53M | 5.37M | 4.38M | 5.82M |
| OtherCurrentLiabilities | 139.00 | 100.00K | -26.92K | |
| CurrentDebtAndCapitalLeaseObligation | 66.91K | 107.13K | 107.18K | 57.63K |
| CurrentCapitalLeaseObligation | 66.91K | 107.13K | 107.18K | 57.63K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 875.91K | 530.70K | 729.20K | 656.27K |
| PayablesAndAccruedExpenses | 2.59M | 4.64M | 3.55M | 5.11M |
| CurrentAccruedExpenses | 2.02M | 4.02M | 1.77M | 2.36M |
| Payables | 573.81K | 611.56K | 1.78M | 5.11M |
| OtherPayable | 19.25K | 14.43K | 33.91K | 57.62K |
| TotalTaxPayable | 16.28K | 15.99K | 27.93K | 26.92K |
| AccountsPayable | 538.28K | 581.14K | 1.72M | 5.08M |
| TotalAssets | 46.03M | 19.22M | 27.32M | 41.36M |
| TotalNonCurrentAssets | 155.17K | 186.88K | 268.86K | 218.52K |
| NetPPE | 155.17K | 186.88K | 268.86K | 218.52K |
| AccumulatedDepreciation | -432.20K | -459.93K | -514.54K | -646.55K |
| GrossPPE | 155.17K | 186.88K | 728.79K | 733.06K |
| OtherProperties | 155.17K | 186.88K | 728.79K | 733.06K |
| CurrentAssets | 45.87M | 19.04M | 27.05M | 41.14M |
| OtherCurrentAssets | 41.81K | 40.67K | 39.76K | 10.23K |
| PrepaidAssets | 1.23M | 2.32M | 2.57M | 1.60M |
| Receivables | 3.94M | 4.04M | 8.67M | 4.73M |
| TaxesReceivable | 3.94M | 4.04M | 8.60M | 4.73M |
| AccruedInterestReceivable | 0.00 | 157.00 | 656.00 | 18.00 |
| AccountsReceivable | 0.00 | 65.23K | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 40.66M | 12.64M | 15.77M | 34.81M |
| OtherShortTermInvestments | 7.50M | 0.00 | ||
| CashAndCashEquivalents | 33.16M | 12.64M | 15.77M | 34.81M |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| FreeCashFlow | -11.45M | -12.61M | -20.04M | -12.43M |
| RepaymentOfDebt | -127.10K | -10.37K | -59.92K | -34.51K |
| IssuanceOfCapitalStock | 42.57M | 10.14M | 316.68K | 17.18M |
| CapitalExpenditure | -5.72K | -7.31K | -89.15K | -10.47K |
| EndCashPosition | 33.16M | 12.64M | 15.77M | 34.81M |
| BeginningCashPosition | 12.64M | 15.77M | 34.81M | 28.12M |
| EffectOfExchangeRateChanges | -198.38K | 260.36K | 914.94K | 2.81M |
| ChangesInCash | 20.72M | -3.40M | -19.95M | 3.88M |
| FinancingCashFlow | 39.67M | 9.22M | 124.34K | 16.30M |
| CashFlowFromContinuingFinancingActivities | 39.67M | 9.22M | 124.34K | 16.30M |
| NetOtherFinancingCharges | -2.77M | -918.02K | -132.41K | -836.97K |
| NetCommonStockIssuance | 42.57M | 10.14M | 316.68K | 17.18M |
| CommonStockIssuance | 42.57M | 10.14M | 316.68K | 17.18M |
| NetIssuancePaymentsOfDebt | -127.10K | -10.37K | -59.92K | -34.51K |
| NetLongTermDebtIssuance | -127.10K | -10.37K | -59.92K | -34.51K |
| LongTermDebtPayments | -127.10K | -10.37K | -59.92K | -34.51K |
| InvestingCashFlow | -7.50M | -5.72K | -36.46K | -89.15K |
| CashFlowFromContinuingInvestingActivities | -7.50M | -5.72K | -36.46K | -89.15K |
| NetOtherInvestingChanges | -29.15K | |||
| NetInvestmentPurchaseAndSale | -7.50M | 0.00 | 0.00 | |
| PurchaseOfInvestment | -7.50M | 0.00 | 0.00 | |
| NetPPEPurchaseAndSale | 0.00 | -5.72K | -7.31K | -89.15K |
| PurchaseOfPPE | 0.00 | -5.72K | -7.31K | -89.15K |
| OperatingCashFlow | -11.45M | -12.61M | -20.04M | -12.34M |
| CashFlowFromContinuingOperatingActivities | -11.45M | -12.61M | -20.04M | -12.34M |
| ChangeInWorkingCapital | -613.68K | 5.75M | -6.39M | 1.76M |
| ChangeInOtherWorkingCapital | 345.21K | -218.01K | 78.69K | 122.88K |
| ChangeInOtherCurrentLiabilities | -99.86K | -11.94K | 0.00 | 0.00 |
| ChangeInOtherCurrentAssets | 1.08M | 252.99K | -968.21K | -516.18K |
| ChangeInPayablesAndAccruedExpense | -2.04M | 1.10M | -1.56M | 2.60M |
| ChangeInPayable | -2.04M | 1.10M | -1.56M | 2.60M |
| ChangeInReceivables | 104.07K | 4.62M | -3.94M | -447.68K |
| OtherNonCashItems | 450.06K | 61.00 | 1.88M | |
| StockBasedCompensation | 979.92K | 881.95K | 966.57K | 1.51M |
| AssetImpairmentCharge | 0.00 | 0.00 | 10.23K | 0.00 |
| DepreciationAmortizationDepletion | 139.72K | 147.53K | 102.26K | 54.21K |
| DepreciationAndAmortization | 139.72K | 147.53K | 102.26K | 54.21K |
| Depreciation | 139.72K | 147.53K | 102.26K | 54.21K |
| OperatingGainsLosses | -259.43K | -261.15K | -917.65K | -2.81M |
| NetForeignCurrencyExchangeGainLoss | -259.43K | -261.15K | -917.65K | -2.81M |
| NetIncomeFromContinuingOperations | -12.15M | -19.12M | -13.81M | -12.85M |
| CashFlowsfromusedinOperatingActivitiesDirect | -11.45M | -12.61M | -20.04M | -12.34M |
| TaxesRefundPaidDirect | 5.56M | 8.53M | -103.45K | 4.08M |
| InterestReceivedDirect | 446.29K | 269.07K | 15.80K | 2.75K |
| InterestPaidDirect | 0.00 | -7.22K | -4.57K | -2.29K |
| ClassesofCashPayments | -17.53M | -21.45M | -20.05M | -16.92M |
| PaymentstoSuppliersforGoodsandServices | -17.46M | -21.39M | -19.94M | -16.88M |
| ClassesofCashReceiptsfromOperatingActivities | 5.63M | 8.58M | 4.58M | 371.36K |
| OtherCashReceiptsfromOperatingActivities | 454.12K | 158.13K | ||
| ReceiptsfromGovernmentGrants | 0.00 | 454.12K | 213.24K |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for ATHE
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|